Pipeline Highlights
— 35 rAAV/antigen vectors having been established in our vector library
— Combining selective vectors to develop various T cell products
— Enabling a single T cell product to treat multiple cancers
— Covering most solid tumors with flexible vector combination
— Making customized products with better efficacy and less side effects
Indications for AAVOT Therapy
Prostate Cancer — Current
Non-small Cell Lung Adenocarcinoma
Non-small Cell Lung Adenocarcinoma
IND filing ongoing
Non-small Cell Lung Adenocarcinoma
Non-small Cell Lung Adenocarcinoma
Non-small Cell Lung Adenocarcinoma
Intestinal Cancer
Non-small Cell Lung Adenocarcinoma
Intestinal Cancer
Kidney Cancer
Cervical Cancer
Intestinal Cancer
Gastric Cancer
Cervical Cancer
Cervical Cancer
Cervical Cancer
Cervical Cancer
Cervical Cancer
Skin Cancer
Malignant Melanoma
Malignant Melanoma
Malignant Melanoma
Malignant Melanoma
Malignant Melanoma
Breast Cancer
Malignant Melanoma
Bone Carcinoma
Bone Carcinoma
Nasopharyngeal Cancer
Bone Carcinoma
Nasopharyngeal Cancer
Nasopharyngeal Cancer
Nasopharyngeal Cancer